Assessment of Effects on Ovarian Activity of a Combined Oral Contraceptive Pill When Preceded by the Intake of ellaOne® or Placebo.

A Prospective, Randomized, Double-blind Parallel-arm, Placebo-controlled Study to Assess the Effects on Ovarian Activity of a Combined Oral Contraceptive Pill When Preceded by the Intake of ellaOne® (Ulipristal Acetate 30 mg) or Placebo.

The purposes of this study are to compare the effects on ovarian activity of quick starting a Combined Oral Contraceptive Pill (COCP) after ellaOne® or placebo intake.

Inclusion Criteria:

• Healthy women aged 18-35 years old
• BMI < 30 Kg/m2
• Not at risk of pregnancy
• No use of progesterone-only-pill for 3 months before start of treatment cycle
• No use of implant hormonal contraception for 3 months before start of treatment cycle
• No use of levonorgestrel intrauterine system for 3 months before start of treatment cycle
• No use of depo provera for 12 months before start of treatment cycle
• Able to give informed consent.